Global Metachromatic Leukodystrophy Treatment 麻豆原创 Growth (Status and Outlook) 2025-2031

Publication ID:

LPI03257672

Publication Date:

March 4, 2025

Pages:

122

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Metachromatic Leukodystrophy Treatment market size is predicted to grow from US$ 218 million in 2025 to US$ 274 million in 2031; it is expected to grow at a CAGR of 3.8% from 2025 to 2031.
Metachromatic leukodystrophy disease (MLD) is a deadly genetic condition caused by mutations in the ARSA gene that results in brain impairment and developmental retardation. In its most severe and prevalent forms, young children rapidly lose their capacity to walk, communicate, and interact with their surroundings, and the majority die before reaching puberty.Metachromatic leukodystrophy is characterized by sulfatide deposition in cells. This accumulating has a particular impact on nervous system cells that create myelin, a material that insulates and protects neurons. White matter is a tissue made composed of nerve cells coated with myelin. This damages the protective myelin sheathing the neurons, leading to gradual deterioration of the brain and nervous system functioning.This disease has three forms that are Late Infantile Form, Juvenile Form, and Adult Form. Pipeline products, which can only treat symptoms of the disease, are among the medical treatment. These products have the potential to prevent nerve damage, reduce the development of the illness, avoid complications, and provide pain relief.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The 鈥淢etachromatic Leukodystrophy Treatment Industry Forecast鈥� looks at past sales and reviews total world Metachromatic Leukodystrophy Treatment sales in 2024, providing a comprehensive analysis by region and market sector of projected Metachromatic Leukodystrophy Treatment sales for 2025 through 2031. With Metachromatic Leukodystrophy Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Metachromatic Leukodystrophy Treatment industry.
This Insight Report provides a comprehensive analysis of the global Metachromatic Leukodystrophy Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Metachromatic Leukodystrophy Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Metachromatic Leukodystrophy Treatment market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Metachromatic Leukodystrophy Treatment and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Metachromatic Leukodystrophy Treatment.
This report presents a comprehensive overview, market shares, and growth opportunities of Metachromatic Leukodystrophy Treatment market by product type, application, key players and key regions and countries.
Segmentation by Type:
Tablet
Capsule
Others
Segmentation by Application:
Hospital
Clinic
Laboratory
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
ArmaGen, Inc.
GlaxoSmithKline Plc
Recursion Pharmaceuticals, Inc.
RegenxBio, Inc.
Takeda Pharmaceutical Company Limited
Orchard Therapeutics Plc
Magenta Therapeutics
Shire Plc
Oxyrane
NanoMedSyn
Juventas Therapeutics
GenSight Biologics
Inozyme Pharma
ONL Therapeutics
AngioChem
Cabaletta Bio

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Metachromatic Leukodystrophy Treatment 麻豆原创 Size (2020-2031)
2.1.2 Metachromatic Leukodystrophy Treatment 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Country/Region (2020, 2024 & 2031)
2.2 Metachromatic Leukodystrophy Treatment Segment by Type
2.2.1 Tablet
2.2.2 Capsule
2.2.3 Others
2.3 Metachromatic Leukodystrophy Treatment 麻豆原创 Size by Type
2.3.1 Metachromatic Leukodystrophy Treatment 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Metachromatic Leukodystrophy Treatment 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Metachromatic Leukodystrophy Treatment Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Laboratory
2.4.4 Others
2.5 Metachromatic Leukodystrophy Treatment 麻豆原创 Size by Application
2.5.1 Metachromatic Leukodystrophy Treatment 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Metachromatic Leukodystrophy Treatment 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Metachromatic Leukodystrophy Treatment 麻豆原创 Size by Player
3.1 Metachromatic Leukodystrophy Treatment 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Metachromatic Leukodystrophy Treatment Revenue by Player (2020-2025)
3.1.2 Global Metachromatic Leukodystrophy Treatment Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Metachromatic Leukodystrophy Treatment Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Metachromatic Leukodystrophy Treatment by Region
4.1 Metachromatic Leukodystrophy Treatment 麻豆原创 Size by Region (2020-2025)
4.2 Global Metachromatic Leukodystrophy Treatment Annual Revenue by Country/Region (2020-2025)
4.3 Americas Metachromatic Leukodystrophy Treatment 麻豆原创 Size Growth (2020-2025)
4.4 APAC Metachromatic Leukodystrophy Treatment 麻豆原创 Size Growth (2020-2025)
4.5 Europe Metachromatic Leukodystrophy Treatment 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Metachromatic Leukodystrophy Treatment 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Metachromatic Leukodystrophy Treatment 麻豆原创 Size by Country (2020-2025)
5.2 Americas Metachromatic Leukodystrophy Treatment 麻豆原创 Size by Type (2020-2025)
5.3 Americas Metachromatic Leukodystrophy Treatment 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Metachromatic Leukodystrophy Treatment 麻豆原创 Size by Region (2020-2025)
6.2 APAC Metachromatic Leukodystrophy Treatment 麻豆原创 Size by Type (2020-2025)
6.3 APAC Metachromatic Leukodystrophy Treatment 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Metachromatic Leukodystrophy Treatment 麻豆原创 Size by Country (2020-2025)
7.2 Europe Metachromatic Leukodystrophy Treatment 麻豆原创 Size by Type (2020-2025)
7.3 Europe Metachromatic Leukodystrophy Treatment 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Metachromatic Leukodystrophy Treatment by Region (2020-2025)
8.2 Middle East & Africa Metachromatic Leukodystrophy Treatment 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Metachromatic Leukodystrophy Treatment 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Metachromatic Leukodystrophy Treatment 麻豆原创 Forecast
10.1 Global Metachromatic Leukodystrophy Treatment Forecast by Region (2026-2031)
10.1.1 Global Metachromatic Leukodystrophy Treatment Forecast by Region (2026-2031)
10.1.2 Americas Metachromatic Leukodystrophy Treatment Forecast
10.1.3 APAC Metachromatic Leukodystrophy Treatment Forecast
10.1.4 Europe Metachromatic Leukodystrophy Treatment Forecast
10.1.5 Middle East & Africa Metachromatic Leukodystrophy Treatment Forecast
10.2 Americas Metachromatic Leukodystrophy Treatment Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Metachromatic Leukodystrophy Treatment Forecast
10.2.2 Canada 麻豆原创 Metachromatic Leukodystrophy Treatment Forecast
10.2.3 Mexico 麻豆原创 Metachromatic Leukodystrophy Treatment Forecast
10.2.4 Brazil 麻豆原创 Metachromatic Leukodystrophy Treatment Forecast
10.3 APAC Metachromatic Leukodystrophy Treatment Forecast by Region (2026-2031)
10.3.1 China Metachromatic Leukodystrophy Treatment 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Metachromatic Leukodystrophy Treatment Forecast
10.3.3 Korea 麻豆原创 Metachromatic Leukodystrophy Treatment Forecast
10.3.4 Southeast Asia 麻豆原创 Metachromatic Leukodystrophy Treatment Forecast
10.3.5 India 麻豆原创 Metachromatic Leukodystrophy Treatment Forecast
10.3.6 Australia 麻豆原创 Metachromatic Leukodystrophy Treatment Forecast
10.4 Europe Metachromatic Leukodystrophy Treatment Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Metachromatic Leukodystrophy Treatment Forecast
10.4.2 France 麻豆原创 Metachromatic Leukodystrophy Treatment Forecast
10.4.3 UK 麻豆原创 Metachromatic Leukodystrophy Treatment Forecast
10.4.4 Italy 麻豆原创 Metachromatic Leukodystrophy Treatment Forecast
10.4.5 Russia 麻豆原创 Metachromatic Leukodystrophy Treatment Forecast
10.5 Middle East & Africa Metachromatic Leukodystrophy Treatment Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Metachromatic Leukodystrophy Treatment Forecast
10.5.2 South Africa 麻豆原创 Metachromatic Leukodystrophy Treatment Forecast
10.5.3 Israel 麻豆原创 Metachromatic Leukodystrophy Treatment Forecast
10.5.4 Turkey 麻豆原创 Metachromatic Leukodystrophy Treatment Forecast
10.6 Global Metachromatic Leukodystrophy Treatment Forecast by Type (2026-2031)
10.7 Global Metachromatic Leukodystrophy Treatment Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Metachromatic Leukodystrophy Treatment Forecast
11 Key Players Analysis
11.1 ArmaGen, Inc.
11.1.1 ArmaGen, Inc. Company Information
11.1.2 ArmaGen, Inc. Metachromatic Leukodystrophy Treatment Product Offered
11.1.3 ArmaGen, Inc. Metachromatic Leukodystrophy Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 ArmaGen, Inc. Main Business Overview
11.1.5 ArmaGen, Inc. Latest Developments
11.2 GlaxoSmithKline Plc
11.2.1 GlaxoSmithKline Plc Company Information
11.2.2 GlaxoSmithKline Plc Metachromatic Leukodystrophy Treatment Product Offered
11.2.3 GlaxoSmithKline Plc Metachromatic Leukodystrophy Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 GlaxoSmithKline Plc Main Business Overview
11.2.5 GlaxoSmithKline Plc Latest Developments
11.3 Recursion Pharmaceuticals, Inc.
11.3.1 Recursion Pharmaceuticals, Inc. Company Information
11.3.2 Recursion Pharmaceuticals, Inc. Metachromatic Leukodystrophy Treatment Product Offered
11.3.3 Recursion Pharmaceuticals, Inc. Metachromatic Leukodystrophy Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 Recursion Pharmaceuticals, Inc. Main Business Overview
11.3.5 Recursion Pharmaceuticals, Inc. Latest Developments
11.4 RegenxBio, Inc.
11.4.1 RegenxBio, Inc. Company Information
11.4.2 RegenxBio, Inc. Metachromatic Leukodystrophy Treatment Product Offered
11.4.3 RegenxBio, Inc. Metachromatic Leukodystrophy Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 RegenxBio, Inc. Main Business Overview
11.4.5 RegenxBio, Inc. Latest Developments
11.5 Takeda Pharmaceutical Company Limited
11.5.1 Takeda Pharmaceutical Company Limited Company Information
11.5.2 Takeda Pharmaceutical Company Limited Metachromatic Leukodystrophy Treatment Product Offered
11.5.3 Takeda Pharmaceutical Company Limited Metachromatic Leukodystrophy Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 Takeda Pharmaceutical Company Limited Main Business Overview
11.5.5 Takeda Pharmaceutical Company Limited Latest Developments
11.6 Orchard Therapeutics Plc
11.6.1 Orchard Therapeutics Plc Company Information
11.6.2 Orchard Therapeutics Plc Metachromatic Leukodystrophy Treatment Product Offered
11.6.3 Orchard Therapeutics Plc Metachromatic Leukodystrophy Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 Orchard Therapeutics Plc Main Business Overview
11.6.5 Orchard Therapeutics Plc Latest Developments
11.7 Magenta Therapeutics
11.7.1 Magenta Therapeutics Company Information
11.7.2 Magenta Therapeutics Metachromatic Leukodystrophy Treatment Product Offered
11.7.3 Magenta Therapeutics Metachromatic Leukodystrophy Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 Magenta Therapeutics Main Business Overview
11.7.5 Magenta Therapeutics Latest Developments
11.8 Shire Plc
11.8.1 Shire Plc Company Information
11.8.2 Shire Plc Metachromatic Leukodystrophy Treatment Product Offered
11.8.3 Shire Plc Metachromatic Leukodystrophy Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 Shire Plc Main Business Overview
11.8.5 Shire Plc Latest Developments
11.9 Oxyrane
11.9.1 Oxyrane Company Information
11.9.2 Oxyrane Metachromatic Leukodystrophy Treatment Product Offered
11.9.3 Oxyrane Metachromatic Leukodystrophy Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.9.4 Oxyrane Main Business Overview
11.9.5 Oxyrane Latest Developments
11.10 NanoMedSyn
11.10.1 NanoMedSyn Company Information
11.10.2 NanoMedSyn Metachromatic Leukodystrophy Treatment Product Offered
11.10.3 NanoMedSyn Metachromatic Leukodystrophy Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.10.4 NanoMedSyn Main Business Overview
11.10.5 NanoMedSyn Latest Developments
11.11 Juventas Therapeutics
11.11.1 Juventas Therapeutics Company Information
11.11.2 Juventas Therapeutics Metachromatic Leukodystrophy Treatment Product Offered
11.11.3 Juventas Therapeutics Metachromatic Leukodystrophy Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.11.4 Juventas Therapeutics Main Business Overview
11.11.5 Juventas Therapeutics Latest Developments
11.12 GenSight Biologics
11.12.1 GenSight Biologics Company Information
11.12.2 GenSight Biologics Metachromatic Leukodystrophy Treatment Product Offered
11.12.3 GenSight Biologics Metachromatic Leukodystrophy Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.12.4 GenSight Biologics Main Business Overview
11.12.5 GenSight Biologics Latest Developments
11.13 Inozyme Pharma
11.13.1 Inozyme Pharma Company Information
11.13.2 Inozyme Pharma Metachromatic Leukodystrophy Treatment Product Offered
11.13.3 Inozyme Pharma Metachromatic Leukodystrophy Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.13.4 Inozyme Pharma Main Business Overview
11.13.5 Inozyme Pharma Latest Developments
11.14 ONL Therapeutics
11.14.1 ONL Therapeutics Company Information
11.14.2 ONL Therapeutics Metachromatic Leukodystrophy Treatment Product Offered
11.14.3 ONL Therapeutics Metachromatic Leukodystrophy Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.14.4 ONL Therapeutics Main Business Overview
11.14.5 ONL Therapeutics Latest Developments
11.15 AngioChem
11.15.1 AngioChem Company Information
11.15.2 AngioChem Metachromatic Leukodystrophy Treatment Product Offered
11.15.3 AngioChem Metachromatic Leukodystrophy Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.15.4 AngioChem Main Business Overview
11.15.5 AngioChem Latest Developments
11.16 Cabaletta Bio
11.16.1 Cabaletta Bio Company Information
11.16.2 Cabaletta Bio Metachromatic Leukodystrophy Treatment Product Offered
11.16.3 Cabaletta Bio Metachromatic Leukodystrophy Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.16.4 Cabaletta Bio Main Business Overview
11.16.5 Cabaletta Bio Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.